Patent intelligence · US
US 9260511
Antibodies or fragments thereof directed against a Staphylococcus aureus epitope of IsaA or IsaB
Antibodies or fragments thereof directed against a Staphylococcus aureus epitope of IsaA or IsaB
Patent details — US 9260511
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 16, 2016
- Expiration
- Feb 11, 2036
- Applicant
- Julius-Maximilians-Universitat Wurzburg
- Claims
- 11
- CPC classes
- A61K, A61K39/40, A61K45/06, A61P
Quick answer
US 9260511 (Antibodies or fragments thereof directed against a Staphylococcus aureus epitope of IsaA or IsaB) is held by Julius-Maximilians-Universitat Wurzburg. Status: granted. Granted Feb 16, 2016. Expires Feb 11, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Julius-Maximilians-Universitat Wurzburg
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K39/40, A61K45/06, A61P, A61P15/14, A61P31/04
More from Julius-Maximilians-Universitat Wurzburg
Related pharmaceutical patents in our USPTO index.
-
US 12391732
Articles comprising a silk polypeptide for antigen delivery
granted -
US 12379385
Methods of treating patients afflicted with irritable bowel syndrome, inflammatory bowel disease or chronic gastrointestinal functional disorders based on assessment of intestinal barrier function
granted -
US 12318397
Methods and compositions for testosterone production
granted -
US 12290524
Methods and compositions for testosterone production
granted -
US 12171837
Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates
granted -
US 12168718
Thermogelling supramolecular sponge as self-healing and biocompatible hydrogel
granted -
US 12144876
Security mechanisms for radiopharmaceutical elution system and elution process
granted -
US 12133890
Antigen-binding polypeptide targeting B7H3 and application thereof
granted
Frequently asked questions
What is US patent 9260511?
US 9260511 (Antibodies or fragments thereof directed against a Staphylococcus aureus epitope of IsaA or IsaB) is held by Julius-Maximilians-Universitat Wurzburg. Status: granted. Granted Feb 16, 2016. Expires Feb 11, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9260511?
Julius-Maximilians-Universitat Wurzburg is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 138 pharmaceutical patents for this assignee.
When does US 9260511 expire?
Our index shows an expiration date of Feb 11, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.